Medical Devices Neutral 5

Nyxoah and Alumis Report Q4 Earnings Misses Amid Clinical Scaling Pressures

Both Nyxoah and Alumis reported quarterly earnings that missed analyst expectations by $0.04 per share, reflecting the high operational costs of late-stage clinical trials and pre-commercialization activities. Despite the financial shortfall, both companies remain on track with pivotal regulatory and clinical milestones in the sleep apnea and immunology sectors.

· 3 min read · Verified by 2 sources · By Healthcare Intelligence Brief Editorial
Share

Key Takeaways

  • Both Nyxoah and Alumis reported quarterly earnings that missed analyst expectations by $0.04 per share, reflecting the high operational costs of late-stage clinical trials and pre-commercialization activities.
  • Despite the financial shortfall, both companies remain on track with pivotal regulatory and clinical milestones in the sleep apnea and immunology sectors.

Mentioned

Nyxoah company NYXH Alumis company ALMS Inspire Medical Systems company INSP Bristol Myers Squibb company

Key Intelligence

Key Facts

  1. 1Nyxoah (NYXH) missed Q4 EPS estimates by $0.04 per share.
  2. 2Alumis (ALMS) reported a matching $0.04 EPS miss against analyst expectations.
  3. 3Nyxoah is currently awaiting FDA review for its Genio neurostimulation system for sleep apnea.
  4. 4Alumis is advancing ESK-001, a selective TYK2 inhibitor for immune-mediated diseases.
  5. 5Both companies are in high-expenditure phases related to late-stage clinical trials and commercial prep.
  6. 6The earnings reports were released on March 20, 2026.
Market Reaction to Earnings Miss

Analysis

The recent quarterly earnings reports from Nyxoah (NASDAQ: NYXH) and Alumis (NASDAQ: ALMS) underscore a persistent challenge for growth-stage healthcare companies: balancing the high costs of clinical innovation with the market's demand for fiscal predictability. Both firms reported an earnings-per-share (EPS) miss of $0.04 relative to consensus estimates, a figure that, while modest in absolute terms, highlights the intensifying burn rates associated with late-stage development and the preparation for large-scale commercial launches.

For Nyxoah, a medical technology firm focused on treating obstructive sleep apnea (OSA), the earnings miss comes at a critical juncture. The company is currently navigating the final stages of the U.S. regulatory pathway for its Genio system, a leadless, battery-free neurostimulator. The Genio system represents a significant technological shift from the current market leader, Inspire Medical Systems, by offering a bilateral stimulation approach that does not require a chest-implanted battery. The financial shortfall likely reflects increased spending on the DREAM pivotal study and the buildup of a U.S. commercial infrastructure. As Nyxoah prepares to challenge a dominant incumbent, the market is closely watching its ability to manage cash reserves while ensuring a flawless regulatory submission to the FDA.

The $0.04 EPS miss for Alumis is indicative of the substantial capital requirements needed to fund Phase 2 and Phase 3 clinical trials in a therapeutic area that is becoming increasingly crowded.

Simultaneously, Alumis, a clinical-stage biopharmaceutical company, is facing similar financial pressures in the high-stakes immunology market. Alumis is primarily focused on developing ESK-001, a highly selective TYK2 inhibitor designed to treat psoriasis and other immune-mediated diseases. The $0.04 EPS miss for Alumis is indicative of the substantial capital requirements needed to fund Phase 2 and Phase 3 clinical trials in a therapeutic area that is becoming increasingly crowded. With Bristol Myers Squibb’s Sotyktu already established in the TYK2 space, Alumis is positioning its candidate as a 'precision' alternative with potentially superior selectivity. The increased expenditure reported this quarter suggests an acceleration in trial enrollment and data analysis efforts, which are essential for the company to maintain its competitive timeline.

What to Watch

From a broader market perspective, these earnings misses reflect a sector-wide trend where clinical-stage volatility remains high. Investors in the healthcare and health IT sectors are currently operating in an environment where 'near-misses' on earnings are often tolerated if they are accompanied by positive clinical data or regulatory progress. However, the consistent $0.04 deviation across two distinct sub-sectors—medical devices and biotechnology—suggests that inflationary pressures on clinical trial labor, specialized manufacturing, and regulatory consulting may be higher than analysts initially modeled for the quarter.

Looking ahead, the narrative for both companies will shift from quarterly financial metrics to binary clinical outcomes. For Nyxoah, the primary catalyst will be the FDA’s decision on the Genio system, which could fundamentally alter the competitive landscape of the multi-billion dollar OSA market. For Alumis, the focus remains on the upcoming data readouts for ESK-001, which will determine if the company can truly differentiate itself from existing TYK2 inhibitors. In both cases, the $0.04 miss is a secondary concern compared to the long-term value proposition of their respective platforms. Analysts will be looking for management to provide clearer guidance on cash runways and the expected timing of revenue generation as these products move closer to the patient bedside.

Sources

Sources

Based on 2 source articles

Cite This Page

"Nyxoah and Alumis Report Q4 Earnings Misses Amid Clinical Scaling Pressures." Healthcare Intelligence Brief, March 20, 2026. https://gethealthbrief.com/story/nyxoah-alumis-q4-earnings-miss-analysis

Related Stories

Medical Devices

Abbott lifts 2026 EPS forecast to $5.45-$5.60 on 9% device growth

Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.

Medical Devices

Floating Robot with Zero Pinch Points Could Redefine Safe Patient Interaction

A new soft floating robot with zero mechanical pinch points could become a safe companion for patients in healthcare settings, reducing injury risk during human-robot interaction. The demo from Keio University and MIT Media Lab highlights gentle, full-body movements that may help elderly or cognitively impaired users feel at ease without the whirring and rigidity of traditional robots.

Medical Devices

Insulet’s Omnipod Defect, Embecta’s 93% Dividend Cut Spark Securities Fraud Suits

Medical device makers Insulet and Embecta face class actions alleging hidden defects and demand weaknesses for insulin delivery products, causing steep investor losses.

Medical Devices

ResMed Faces $270.64 Consensus Target Amid Analyst Divide on Sleep Device Demand

Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.

How we covered this story

Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled healthcare-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.